The proposed bill aims to prohibit pharmaceutical manufacturers from restricting or limiting the distribution of prescription medications to a limited network of out-of-state pharmacies. It introduces a new section to the Arkansas Code, which emphasizes the importance of patient access to prescription drugs and pharmacy services. The bill outlines legislative findings that highlight the potential harm to patients when local pharmacies are unable to access necessary medications due to these restrictions. It also calls for increased transparency and oversight regarding limited distribution networks, which are often complex and lack clarity.

Additionally, the bill mandates that pharmaceutical manufacturers must not limit access to prescription medications for more than three months after a new product launch without providing local pharmacies the opportunity to participate in the distribution network. It establishes criteria for compliance, including the requirement for manufacturers to hold an active wholesale distributor permit and to allow local pharmacies to access medications upon request. Noncompliance with these regulations could result in significant fines. The bill also includes a severability clause and sets a compliance deadline for manufacturers by September 1, 2026.